Respuesta :
Answer:
1) The new antipyretic (Feverstop) is more effective than the placebo
Step-by-step explanation:
Significant Level (α)
Significant level is the measure of the probability that the event could have occurred by chance.
- If the Probability is higher than the Significant level (p-value > α) → indicates the event can occur by chance → the event is not significant → We do not have enough evident to reject the null Hypothesis (H₀).
- If the Probability is lower than the Significant level (p-value < α) → indicates the event rarely happens → the event is significant → We have enough evident to reject the null hypothesis and accept the alternate hypothesis (Ha).
In this question, the p-value is lower than the significant level, therefore we can reject the H₀ (new antipyretic is not more effective) and accept the Ha (new antipyretic is more effective).
Note: Since the trial is for testing if the Feverstop has higher success, therefore the choice is only between no higher success or higher success (will not result in less success).
Final answer:
The new antipyretic Feverstop is more effective than the placebo in reducing fever, as indicated by a p-value lower than the alpha level of 0.05, denoting statistical significance in the clinical trial.
Explanation:
Based on the information provided from the clinical trial of a new antipyretic named Feverstop versus placebo, where the report concluded that Feverstop gave a higher proportion of success than the placebo and the study is statistically significant with a p-value < 0.05, we can conclude that the new antipyretic (Feverstop) is more effective than the placebo. When the alpha level (significance level) is set at 0.05, and the p-value obtained is less than this threshold, it indicates that there is less than a 5% chance that the observed differences were due to random variation alone. Therefore, the conclusion is that Feverstop shows a statistically significant improvement in reducing fever compared to the placebo.
